Akanda Corp Com
| NASDAQ: AKAN | Healthcare / Drug Manufacturers / United Kingdom |
| 0.5200 | -0.0170 | -3.17% | Vol 30.75K | 1Y Perf 41.32% |
| Oct 4th, 2023 15:50 DELAYED |
| BID | 0.5200 | ASK | 0.5500 | ||
| Open | 0.5370 | Previous Close | 0.5370 | ||
| Pre-Market | 0.54 | After-Market | - | ||
| 0.00 -0.24% | - - |
| Target Price | - | Analyst Rating | — — 0.00 | |
| Potential % | - | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★+ 44.12 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 1.35 | Earnings Rating | — | |
| Market Cap | 2.02M | Earnings Date | 7th Aug 2023 | |
| Alpha | -0.14 | Standard Deviation | 0.40 | |
| Beta | 1.79 |
Today's Price Range 0.50100.5512 | 52W Range 0.44006.35 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -6.93% | ||
| 1 Month | 2.58% | ||
| 3 Months | -26.55% | ||
| 6 Months | -44.92% | ||
| 1 Year | 41.32% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | -26.13 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -20.82 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -20.67 | |||
Return on invested Capital Q | -18.09 | |||
Return on invested Capital Y | -18.09 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.20 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.50 | ||||
| 0.17 | ||||
| 88.47 | ||||
| - | ||||
| -0.50 | ||||
| -0.45 | ||||
| 0.52 | ||||
| 1.02 | ||||
| 5.44M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.80 | ||||
| 1.10 | ||||
| 0.07 | ||||
| 0.11 | ||||
| -5.00 | ||||
| Leverage Ratio | 1.30 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -560.20 | ||||
| -5 155.90 | ||||
| -3 490.60 | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 73.10K | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 30.75K |
| Shares Outstanding | 3.88K |
| Shares Float | 3.14M |
| Trades Count | 131 |
| Dollar Volume | 15.84K |
| Avg. Volume | 442.30K |
| Avg. Weekly Volume | 241.38K |
| Avg. Monthly Volume | 659.86K |
| Avg. Quarterly Volume | 425.66K |
Akanda Corp Com (NASDAQ: AKAN) stock closed at 0.537 per share at the end of the most recent trading day (a 4.52% change compared to the prior day closing price) with a volume of 120.92K shares and market capitalization of 2.02M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 0 people. Akanda Corp Com CEO is Tejinder Virk.
The one-year performance of Akanda Corp Com stock is 41.32%, while year-to-date (YTD) performance is 260.4%. AKAN stock has a five-year performance of %. Its 52-week range is between 0.44 and 6.35, which gives AKAN stock a 52-week price range ratio of 1.35%
Akanda Corp Com currently has a PE ratio of -0.50, a price-to-book (PB) ratio of 0.17, a price-to-sale (PS) ratio of 88.47, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -20.82%, a ROC of -20.67% and a ROE of -26.13%. The company’s profit margin is -%, its EBITDA margin is -3 490.60%, and its revenue ttm is $73.10 Thousand , which makes it $0.00 revenue per share.
Of the last four earnings reports from Akanda Corp Com, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Akanda Corp Com’s next earnings report date is -.
The consensus rating of Wall Street analysts for Akanda Corp Com is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Akanda Corp Com stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Akanda Corp Com has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Akanda Corp Com has a Sell technical analysis rating based on Technical Indicators (ADX : 48.51, ATR14 : 0.10, CCI20 : -80.87, Chaikin Money Flow : 0.03, MACD : -0.02, Money Flow Index : 54.17, ROC : -38.85, RSI : 43.61, STOCH (14,3) : 8.29, STOCH RSI : 0.26, UO : 30.13, Williams %R : -91.71), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Akanda Corp Com in the last 12-months were:
Akanda Corp Com
Akanda Corp is an international medical cannabis company cultivating cannabis of the highest quality at scale, leveraging trusted brands, at a low-cost compared to many of its competitors. The company is building a seed-to-patient supply chain, connecting patients in the UK and Europe with diverse products including cannabis products cultivated at its competitively advantaged grow operation in the Kingdom of Lesotho and with other trusted third-party brands.
CEO: Tejinder Virk
Telephone: +44 2034889514
Address: 1A, 1B Learoyd Road, New Romney TN28 8XU, , GB
Number of employees: 0
